Prosetta Biosciences Receives $31,000,000 Series D Funding Round

  • Feed Type
  • Date
    12/4/2015
  • Company Name
    Prosetta Biosciences
  • Mailing Address
    670 Fifth Street San Francisco, CA 94107 USA
  • Company Description
    Prosetta Biosciences, Inc. is a biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle.
  • Website
    http://www.prosetta.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $31,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The net proceeds from the private placement will be used primarily for research and development, with an emphasis in the fields of central nervous system diseases and disorders, oncology, inflammation, antiinfectives, vaccines, animal health and biodefense, among other fields, and for working capital and general corporate purposes.
  • M&A Terms
  • Venture Investor
    Fred Alger Management
  • Venture Investor
    Takeda Ventures